Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals
Arruda, Monica B.
Boullosa, Lidia T.
Cardoso, Cynthia C.
da Costa, Carolina M.
Alves, Carlos R. B.
de Lima, Shirlene T. S.
Kaminski, Helena T.
Aleixo, Agdemir W.
Esposito, Ana O. P.
Cavalcanti, Ana M. S.
Couto-Fernandez, Jose C.
Ferreira, Selma B.
de Oliveira, Ivi C. M.
Portal, Loreci E.
Wolf, Hilda H. C.
Fernandes, Sandra B.
Pardini, Maria I. de M. C.
Feiteiro, Manoel V. C.
Tolentino, Fernanda M.
Diaz, Ricardo Sobhie [UNIFESP]
Lopes, Giselle I. S. L.
Francisco, Roberta B. L.
Veras, Nazle M. C.
Pires, Ana F.
Es parte deJournal Of The International Aids Society
MetadatosMostrar el registro completo del ítem
Introduction: In Brazil, more than 487,450 individuals are currently undergoing antiretroviral treatment. In order to monitor the transmission of drug-resistant strains and HIV subtype distribution in the country, this work aimed to estimate its prevalence and to characterize the nationwide pretreatment drug resistance in individuals recently diagnosed with HIV between 2013 and 2015. Methods: The HIV threshold survey methodology (HIV-THS, WHO) targeting antiretroviral-naive individuals with recent HIV diagnosis was utilized, and subjects were selected from 51 highly populated cities in all five Brazilian macroregions. The HIV pol genotypic test was performed by genomic sequencing. Results: We analysed samples from 1568 antiretroviral-naive individuals recently diagnosed with HIV, and the overall transmitted drug resistance (TDR) prevalence was 9.5% (150 sequences). The regional prevalence of resistance according to Brazilian geographical regions was 9.4% in the northeast, 11.2% in the southeast, 6.8% in the central region, 10.2% in the north and 8.8% in the south. The inhibitor-specific TDR prevalence was 3.6% for nucleoside reverse transcriptase inhibitors (NRTIs), 5.8% for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 1.6% for protease inhibitors (PIs)1.0% of individuals presented resistance to more than one class of inhibitors. Overall, subtype B was more prevalent in every region except for the southern, where subtype C prevails. Conclusions: To the best of our knowledge, this is the first TDR study conducted in Brazil with nationwide representative sampling. The TDR prevalence revealed a moderate rate in the five Brazilian geographical regions, although some cities presented higher TDR prevalence rates, reaching 14% in Sao Paulo, for example. These results further illustrate the importance of surveillance studies for designing future strategies in primary antiretroviral therapy, aiming to mitigate TDR, as well as for predicting future trends in other regions of the globe where mass antiretroviral (ARV) treatment was implemented.
CitaJournal Of The International Aids Society. Chichester, v. 21, n. 3, p. -, 2018.
HIV drug resistance
pretreatment HIV drug resistance
primary antiretroviral resistance
HIV Drug Resistance Surveillance
ResponsávelBrazilian Ministry of Health
- EPM - Artigos 
Mostrando ítems relacionados por Título, autor o materia.
Streptococcus pneumoniae penicillin-nonsusceptible strains in invasive infections in São Paulo, Brazil Berezin, E. N.; Carvalho, E. S.; Casagrande, S.; Brandileone, M. C.; Mimica, I. M.; Farhat, C. K. (Williams & Wilkins, 1996-11-01)
Prevalência de resistência transmitida do HIV-1 aos antirretrovirais no Brasil, pré- início de tratamento Soares, Celina Maria Pereira de Moraes [UNIFESP] (Universidade Federal de São Paulo (UNIFESP), 2011-09-28)The selection of resistance mutations to antiretroviral drugs after failure of antiretroviral therapy represents a major challenge for decision-making of new therapeutic regimens in the global pandemic. The high genetic ...
Gayoso, Maria de Fátima Azevedo [UNIFESP]; Oliveira, Adália Dias Dourado [UNIFESP]; d'Azevedo, Pedro Alves [UNIFESP]; Yu, Maria Cecília Zorat [UNIFESP]; Hofling-Lima, Ana Luisa [UNIFESP]; Francisco, Waldemar (Conselho Brasileiro de Oftalmologia, 2007-12-01)PURPOSE: To assess the in vitro susceptibility of conjunctival and corneal coagulase negative Staphylococcus (CoNS) to methicillin, fluoroquinolones and aminoglycosides. METHODS: A total of 707 conjunctival and corneal ...